ArticleCureus2026
Spontaneous Tumor Lysis Syndrome in Refractory Metastatic Esophageal Adenocarcinoma Presenting With Septic Shock.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Spontaneous tumor lysis syndrome (STLS) presents a diagnostic challenge when it occurs in patients with advanced solid malignancies and concurrent critical illness. We present a case of STLS in a 30-year-old man with refractory metastatic esophageal adenocarcinoma who presented with hypotension, anuria, and severe metabolic derangements. Laboratory evaluation demonstrated hyperuricemia (18.1 mg/dL), hyperkalemia (7.6 mmol/L), hyperphosphatemia (7.8 mg/dL), and acute kidney injury. Ionized calcium was also low at 1.03 mmol/L despite hypoalbuminemia, with laboratory and clinical findings consistent with TLS by Cairo-Bishop thresholds. His final treatment was initiated 19 days before presentation, with the continuous fluorouracil infusion completed approximately 17 days before presentation, placing the presentation well outside the conventional treatment-related timeframe. His course was complicated by septic shock secondary to methicillin-sensitive
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.